Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Major trial tests new pill to protect failing kidneys

NCT ID NCT07419828

Summary

This large, late-stage study is testing whether a new tablet called HRS-1780 can slow the decline of kidney function in adults with chronic kidney disease. Nearly 2,000 participants will take either the new drug or a placebo pill for over two years, in addition to their standard treatments. The main goal is to see if HRS-1780 can better preserve kidney filtering ability compared to the placebo.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National Clinical Research Center of Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University

    RECRUITING

    Nanjing, Jiangsu, 210002, China

    Contact

Conditions

Explore the condition pages connected to this study.